The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 17 of the 19 sources its claims cite were checked for support.
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Open accessAbstract
BACKGROUND: Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized. Although only a small proportion of patients have had a relapse during ibrutinib therapy, an understanding of resistance mechanisms is important. We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance. METHODS: We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy. We then performed functional analysis of identified mutations. In addition, we performed Ion Torrent sequencing for identified resistance mutations on samples from nine patients with prolonged lymphocytosis. RESULTS: We identified a cysteine-to-serine mutation in BTK at the binding site of ibrutinib in five patients and identified three distinct mutations in PLCγ2 in two patients. Functional analysis showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib. The R665W and L845F mutations in PLCγ2 are both potentially gain-of-function mutations that lead to autonomous B-cell-receptor activity. These mutations were not found in any of the patients with prolonged lymphocytosis who were taking ibrutinib. CONCLUSIONS: Resistance to the irreversible BTK inhibitor ibrutinib often involves mutation of a cysteine residue where ibrutinib binding occurs. This finding, combined with two additional mutations in PLCγ2 that are immediately downstream of BTK, underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrutinib in CLL. (Funded by the National Cancer Institute and others.).
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Acquired resistance to ibrutinib in CLL often involves BTK C481S or PLCγ2 mutations that restore B-cell–receptor signaling. Functional studies show C481S prevents irreversible BTK binding, while PLCγ2 R665W/L845F are gain-of-function and BTK-independent.
Key findings
- Whole-exome sequencing of six patients with acquired ibrutinib resistance identified BTK C481S in five patients and PLCγ2 mutations in two patients: R665W in Patient 6, and R665W, L845F, plus S707Y in one patient who also had low-frequency BTK C481S.
- C481S BTK had lower ibrutinib affinity than nonmutant BTK (dissociation constant, 0.2 nM vs. 10.4 nM) and was only reversibly inhibited by ibrutinib; washout experiments in patient cells showed inhibition required continuous drug exposure.
- PLCγ2 R665W and L845F showed enhanced anti-IgM–mediated calcium flux that was not inhibited by ibrutinib, indicating potential gain-of-function mutations allowing BTK-independent B-cell–receptor signaling.
- No BTK or PLCγ2 mutations were found in nine patients with prolonged lymphocytosis (≥12 months) on ibrutinib; sequencing depth was >700 reads for BTK C481 and PLCγ2 R665/S707 and >100 reads for PLCγ2 L845.
Methods
- Whole-exome sequencing was performed on baseline and relapse samples from six patients with acquired resistance to ibrutinib; relapse-specific nonsynonymous mutations were verified by Sanger or Ion Torrent sequencing.
- Ion Torrent sequencing was used to test for BTK and PLCγ2 mutations in nine patients with prolonged lymphocytosis during ibrutinib therapy.
- Functional analyses included in vitro kinase assays, flow cytometry, immunoblot assays, and stable transfection into DT40 or HEK 293T cells; statistical methods were detailed in the Supplementary Appendix.
Limitations
- The paper states that inability to identify small numbers of mutant clones in the presence of large numbers of nonmutant clones may mean such variants were present but not identified; the clinical significance of very low baseline R665W variant reads is unknown and more patients need evaluation.
- The paper states that other resistance mechanisms are likely present in a subgroup of patients without B-cell–receptor pathway mutations, and work is ongoing to identify alternative mechanisms.
- Evident from the text: the study is based on a small number of patients (six with acquired resistance and nine with prolonged lymphocytosis), limiting generalizability and statistical power.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
22 Own result · 20 Own interpretation · 6 Partly supported · 4 Supported · 2 Couldn’t confirm · 2 No full text of the sources · 2 Own method · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In patients treated with ibrutinib, a characteristic lymphocytosis develops as CLL cells are mobilized from lymph nodes and the spleen.”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > ABSENCE OF BTK OR PLCγ2 MUTATIONS IN PATIENTS WITH PROLONGED LYMPHOCYTOSIS DURING IBRUTINIB THERAPY
What the sources say
- Partly supportedcites [24] sourceExperimental — accuracy not yet measured
The Results report that lymphocytosis occurred in 77% of patients treated with ibrutinib, and the Introduction describes cell mobilization from nodal and marrow sites as a possible mechanism. Our copy does not identify the spleen as a source of the mobilized CLL cells, so that part of the claim is unsupported. (LLM, conf=0.85)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although lymphocytosis typically resolves within 8 months, a subgroup of patients have lymphocytosis that lasts longer than 12 months in the presence of a continued response to ibrutinib.24”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > ABSENCE OF BTK OR PLCγ2 MUTATIONS IN PATIENTS WITH PROLONGED LYMPHOCYTOSIS DURING IBRUTINIB THERAPY
What the sources say
- Supportedcites [24] source
The Results (page not specified) report a median time to lymphocyte normalization of 6.2 months and identify patients who still had lymphocytosis at 12 months but otherwise met criteria for a partial response. A second Results passage reports that their progression-free survival was not inferior to that of patients with a conventional partial or complete response. (LLM, conf=0.91)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“whereas dasatinib, a reversible inhibitor of BTK,23 inhibited nonmutant and mutant BTK with similar efficacy.”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > REVERSIBLE INHIBITION OF MUTANT BTK BY IBRUTINIB IN VITRO AND IN PATIENTS
What the sources say
- Partly supportedcites [23] sourceExperimental — accuracy not yet measured
The citation is attached to the description of dasatinib as a reversible BTK inhibitor. The Results establish that dasatinib inhibits BTK, but our copy does not establish that its inhibition is reversible. It also does not test C481S or support the sentence’s comparison of C481S with nonmutant BTK; the mutant it tests is T474I, which was resistant. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL).”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > Abstract > BACKGROUND
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The section on PCI-32765-induced cytotoxicity states that PCI-32765 is an irreversible BTK inhibitor. Our copy does not name ibrutinib or establish that it is the same compound, so it does not fully support the claim as worded. (LLM, conf=0.78)
- Partly supportedcites [8] sourceExperimental — accuracy not yet measured
The Introduction states that PCI-32765 binds irreversibly to BTK, supporting the inhibitor property. Our copy does not identify PCI-32765 as ibrutinib, so it does not establish that the named drug has that property. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“At 26 months, the estimated progression-free survival rate among patients treated with ibrutinib is 75%.9”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > Abstract > CONCLUSIONS
What the sources say
- Supportedcites [9] source
The Results > Efficacy passage reports that the 26-month estimated progression-free survival rate during ibrutinib treatment was 75%, exactly as claimed. This estimate concerns the patients in the cited study. (LLM, conf=0.95)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ibrutinib irreversibly binds BTK at the C481 residue, rendering it kinase-inactive”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Introduction and Discussion describe PCI-32765 as an irreversible BTK inhibitor, and the section on BCR-dependent signaling reports reduced BTK phosphorylation consistent with inhibited kinase activity. Our copy does not identify PCI-32765 as ibrutinib or state that it binds BTK at C481, so those specifics are not established by this source. (LLM, conf=0.84)
- Partly supportedcites [8] sourceExperimental — accuracy not yet measured
The Introduction (page not provided) says PCI-32765 binds irreversibly to a cysteine residue in BTK and inhibits its enzymatic activity. It does not identify that residue as C481; a search for “C481” found no matching passage. The copy calls the drug PCI-32765 rather than ibrutinib. (LLM, conf=0.87)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“At relapse, none of the patients had mutations in other kinases containing a cysteine residue homologous to C481 in BTK that are irreversibly inhibited by ibrutinib”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > MUTATIONS IN BTK AND PLCγ2 REVEALED BY WHOLE-EXOME SEQUENCING
What the sources say
- Could not verifycites [7] sourceExperimental — accuracy not yet measured
The Results and Discussion describe PCI-32765 binding to BTK at Cys-481 and note that a small subset of other kinases has a homologous cysteine. Neither section reports sequencing patients at relapse or whether any had mutations in those kinases; searches for relapse and patient mutations found no such result in our copy. (LLM, conf=0.76)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
The Introduction and Results describe cysteine-dependent irreversible inhibition of BTK and ITK, but do not report mutation testing at relapse. A search for relapsed patients, six patients, and mutations in other kinases found no passage addressing the claim. (LLM, conf=0.75)
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“mutations have not been observed in these other targets, findings that suggest that BTK is its critical target.”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > DISCUSSION
What the sources say
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion reports that BTK inhibition correlated with efficacy in a mouse arthritis model, consistent with BTK being a relevant target in vivo. It does not report acquired-resistance mutations in patients or establish that mutations were absent from ITK, BLK, or other targets. It also says a role for other cysteine-containing kinases cannot be ruled out. (LLM, conf=0.80)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
The Results describe ITK-C442A engineered in Jurkat cells to test ibrutinib binding, not mutations observed in patients with acquired resistance. Searches for acquired-resistance mutations in ITK, BLK, and other targets found no passage addressing whether such mutations were observed; our copy therefore cannot verify the attributed claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We have previously documented by immunoblot analysis24 that BTK and PLCγ2 are inhibited in these patients”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > DISCUSSION
What the sources say
- Supportedcites [24] source
The Results report immunoblot analysis of samples from patients with prolonged lymphocytosis at baseline and six months into ibrutinib therapy. BTK autophosphorylation was down-regulated in 8 of 8 patients, and PLCγ2 phosphorylation was diminished in 7 of 9; the authors conclude that both remain inhibited in most patients with persistent lymphocytosis. (LLM, conf=0.95)
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although ibrutinib inhibits other similar kinases that contain C481, including ITK and BLK,7,22”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > DISCUSSION
What the sources say
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says PCI-32765 binds BTK at Cys-481 and that inhibition of other cysteine-containing kinases, including BLK, cannot be ruled out. It does not establish BLK inhibition or identify ITK as a kinase inhibited by PCI-32765, so the claim is stronger and more specific than this paper supports. (LLM, conf=0.86)
- Partly supportedcites [22] sourceExperimental — accuracy not yet measured
The Results confirm that ibrutinib binds and inhibits ITK, but identify its covalent binding residue as C442, not C481. The passages searched for BLK do not report BLK inhibition, so the source does not support that part of the claim. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
- It may state two separate claims as one. 11
- The quote only partly states this claim. 2
- Probably not a substantial claim. 1
Every source the paper cites for this claim was checked and supports it.
In the paper
“Ibrutinib has been shown to have clinically significant activity in patients with relapsed CLL, with 71% of patients having an objective complete or partial response and an additional 15 to 20% of patients having a partial response with persistent lymphocytosis.”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > Abstract > CONCLUSIONS
What the sources say
- Supportedcites [9] source
The Results > Efficacy passage reports a 71% response rate by standard criteria in each dose cohort. It also reports an additional partial response with persistent lymphocytosis in 20% of the 420-mg cohort and 15% of the 840-mg cohort, matching the cited claim about patients with relapsed CLL. (LLM, conf=0.94)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“This mutation is not known to cause the X-linked agammaglobulinemia phenotype31 but instead results in retained catalytic activity.”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > DISCUSSION
What the sources say
- Could not verifycites [31] sourceExperimental — accuracy not yet measured
The citation is attached to the claim that C481S is not known to cause the X-linked agammaglobulinemia phenotype. The Mutation Statistics section discusses tolerated substitutions generally, but our copy does not address C481S specifically (searched: C481S, 481, and the phenotype claim). The retained-catalytic-activity clause falls after the citation and is not assessed as attributed to this source. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In Patients 3, 5, and 6, Ion Torrent sequencing was performed, and no mutation was identified in more than 0.2% of reads”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > MUTATIONS IN BTK AND PLCγ2 REVEALED BY WHOLE-EXOME SEQUENCING
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In Patient 6, the decrease in BTK phosphorylation at the time of the relapse was similar to the decrease at 11 months of therapy, when the patient was having a response to the drug (Fig. 3A), whereas PLCγ2 showed enhanced phosphorylation at the time of relapse”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > IDENTIFIED MUTATIONS IN PLCγ2 AS RESISTANCE MECHANISMS IN VITRO AND IN PATIENTS
plaincorrelationalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Ibrutinib washout experiments showed that the C481S mutation allows reversible, but not irreversible, inhibition of BTK by ibrutinib”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > REVERSIBLE INHIBITION OF MUTANT BTK BY IBRUTINIB IN VITRO AND IN PATIENTS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, BTK phosphorylation was completely abrogated by ibrutinib with either washout or continuous exposure to ibrutinib. At the time of relapse, however, ibrutinib inhibited BTK phosphorylation only with continuous exposure”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > REVERSIBLE INHIBITION OF MUTANT BTK BY IBRUTINIB IN VITRO AND IN PATIENTS
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After ibrutinib was discontinued, ibrutinib still inhibited BTK phosphorylation (Fig. 3C) but not PLCγ2 phosphorylation (Fig. 3D).”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > IDENTIFIED MUTATIONS IN PLCγ2 AS RESISTANCE MECHANISMS IN VITRO AND IN PATIENTS
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The intrinsic affinity of ibrutinib for nonmutant BTK was significantly higher than for mutant BTK (dissociation constant, 0.2 nM vs. 10.4 nM)”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > REVERSIBLE INHIBITION OF MUTANT BTK BY IBRUTINIB IN VITRO AND IN PATIENTS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data show that the R665W and L845F mutations in PLCγ2 are potentially gain-of-function mutations in the presence of B-cell–receptor stimulation and could be relevant as mutations conferring resistance to ibrutinib in patients.”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > IDENTIFIED MUTATIONS IN PLCγ2 AS RESISTANCE MECHANISMS IN VITRO AND IN PATIENTS
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sequencing depth for BTK at C481 and for PLCγ2 at R665 and S707 was more than 700 reads, and the sequencing depth for PLCγ2 at L845 was more than 100 reads.”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > RESULTS > ABSENCE OF BTK OR PLCγ2 MUTATIONS IN PATIENTS WITH PROLONGED LYMPHOCYTOSIS DURING IBRUTINIB THERAPY
plainn = 9- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Unlike the mutations in this group, however, the C481S mutation in BTK is not a second mutation in a previously mutated gene, but rather a primary mutation in a gene that is not recurrently mutated in CLL, and it is mutated at the amino acid required for drug binding.”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In a recent preliminary study involving three patients with ibrutinib resistance, sequencing revealed the S707Y mutation in PLCγ2 that we identified in Patient 5 in our study but did not reveal BTK mutations.32”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [32] Burger JA, 2013, Blood source
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, we recognize that our inability to identify small numbers of mutant clones in the presence of large numbers of nonmutant clones may mean that such variants were present but were not identified.”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This pattern of a mutation localized to the irreversible binding site of ibrutinib and the immediate downstream kinase is not commonly seen with reversible kinase inhibitors and may be a result of continuous (rather than intermittent) pressure on the drug target.”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, many mutations discovered in PLCγ2 have been linked to the development of complex immune disorders as well as resistance to ibrutinib treatment in chronic lymphocytic leukaemia.”
From Characterisation of molecular mechanisms for PLCγ2 disease-linked variants (2024) · cites this paper as Woyach et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whole-exome sequencing of six CLL patients with late relapses revealed C481S mutations in BTK of five patients and three distinct mutations in PLCG2 of two patients as follows: L845F, R665W, and S707Y in one patient with tumor cells also harboring a BTK C481S mutation and PLCG2 R665W representing the sole mutation in the other patient (29).”
From The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the R665W and L845F mutants of PLC␥ 2 appeared to be functionally normal in reconstituted DT40 chicken B cells in the absence of BCR stimulation, but to mediate moderately enhanced and markedly prolonged ibrutinib-resistant increases in [Ca 2ϩ ] i following BCR ligation with anti-IgM (29).”
From The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ibrutinib, acalabrutinib, and zanubrutinib bind covalently to residue C481 of BTK, and thus are susceptible to mutations changing C481 to another amino acid, most commonly C481S(19–21).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In published studies of disease progression during BTKi therapy,approximately 35% of patients were found to have aBTK mutation alone, an additional 10% had a coexisting mutations in PLCG2, 5% of cases had a PLCG2mutation alone, and the remaining 50% were wild-type (WT) for BTK and PLCG2 (Figure 2)(12, 19, 21–31).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first reported BTK mutation in CLL patients with progressive disease on ibrutinib (19, 35)was a missense mutation changing C481 to serine (C481S)(19).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PLCG2 S707Y, R665W, and L845F are gain-of-function missense mutations which prolong activation of BCR‐mediated downstream signaling, independent of BTK (19).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, genomic deletions (exon 19 or exons 20 through 22) or somatic mutations (R665W or S707Y) within the regulatory domain of PLCG2 constitutively activate PLCG2 and lead to BTK inhibitor resistance in leukemia patients 20,21 .”
From Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer’s disease (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutations in the gene encoding phospholipase C-␥ 2 (PLC␥ 2 ) have been shown to be associated with resistance to targeted therapy of chronic lymphocytic leukemia (CLL) with the Bruton's tyrosine kinase inhibitor ibrutinib.”
The cited source says what the claim attributes to it.
In the citing paper
“The C481S mutation disrupts the covalent binding of ibrutinib to BTK and results in a weak and reversible interaction (affinity [KD], 0.2 nM vs. 10.4 nM) (19).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations of PLCG have been observed to co-occur with BTK mutations in the same patient (12, 19, 24).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [19]
In the citing paper
“the resistance to ibrutinib emerges due to a cysteine to serine mutation (C418S) at the ibrutinib binding site in BTK [113, 114].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > DISCUSSION
“EGFR25,26 and ALK27 in lung cancer”
§ Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib > References
“27. Awad MM Katayama R McTigue M Acquired resistance to crizotinib from a mutation in CD74–ROS1 N Engl J Med 2013 368 2395 2401 23724914 PMC3878821”
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
O’Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T. H., Hochhaus, A., Hughes, T. P., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,550
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationChiorazzi, N., Rai, K. R., & Ferrarini, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041720 · Cited by 1,684
Cited by
Sorted by citations
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B. K., O'Brien, S. M., Jones, J. A., Schuh, A., Devereux, S., Chaves, J. M., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 916
Self-citationPROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 830
“This is observed, for example, when ibrutinib is used for the treatment of chronic lymphocytic leukemia (CLL) [82] ), which is often dependent on the activity of BTK. Ibrutinib is an irreversible kinase inhibitor that covalently binds to a cysteine in the ATP binding pocket of BTK.”
BackgroundThe Inositol Trisphosphate/Calcium Signaling Pathway in Health and Disease
Berridge, M. J. (2016) · Physiological Reviews · doi:10.1152/physrev.00006.2016 · Cited by 779
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
“Two important therapy-associated resistance mechanisms have been identified, involving BTK C481S mutation (the site of action of Ibrutinib) or activating mutations in PLCy2 (R665W, S707Y and L845F) [193, 194].”
BackgroundByrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 674
“Median age, years (range) 71 (65-84) 64 (37-82) 68 (37-84)”
Self-citationTurtle, C. J., Hay, K. A., Hanafi, L., Li, D., Cherian, S., Chen, X., Wood, B. L., Lozanski, A., Byrd, J. C., Heimfeld, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8519 · Cited by 664
Self-citationPROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 663
“However, MCL patients have developed drug resistance after receiving ibrutinib treatment due to the missense BTK mutation of C481S.(165) Ibrutinib also lost the inhibitory efficacy of DLBCL tumor cell growth resulting from the BTK C481S mutant.”
BackgroundJackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.218 · Cited by 584
Self-citationKipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., O'Brien, S. M., Gribben, J. G., & Rai, K. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.96 · Cited by 590
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Hallek, M. J. (2019) · American Journal of Hematology · doi:10.1002/ajh.25595 · Cited by 523
“Six initial patients with acquired resistance to ibrutinib therapy were examined by whole-exome sequencing.(104) A cysteine-to-serine mutation in BTK at the binding site of ibrutinib was found in five patients and three distinct mutations in PLCgamma2 (PLCG2) were identified in two patients.”
BackgroundScherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8545 · Cited by 495
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474
“For in vitro experiments, we briefly exposed T cells to ibrutinib and then performed a wash to allow only for specific and irreversible binding to ITK, rather than nonspecific kinase inhibition.(17,35,36) Supraphysiological doses of ibrutinib did not impair or enhance transduction with the anti-CD19 CAR lentiviral vec…”
Self-citationTargeting cancer with kinase inhibitors
Gross, S. D., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76094 · Cited by 459
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, C. S. L., Anderson, M. A., Pott, C., Agarwal, R., Handunnetti, S. M., Hicks, R. J., Burbury, K., Turner, G. E., Iulio, J. D., Bressel, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715519 · Cited by 429
Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M. K., Kolstad, A., Pedersen, L. B., Montano‐Almendras, C. P., Husby, S., Freiburghaus, C., Ek, S., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779736 · Cited by 414
“Of the remaining 319 patients, the median age was 57 years (29-65), 76% were male gender, 51% were MIPI high- or intermediate-risk, 18%”
BackgroundBuhimschi, A. D., Armstrong, H. A., Toure, M., Jaime-Figueroa, S., Chen, T. L., Lehman, A. M., Woyach, J. A., Johnson, A. J., Byrd, J. C., & Crews, C. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00391 · Cited by 394
Self-citationChronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Hallek, M. J., & Al‐Sawaf, O. (2021) · American Journal of Hematology · doi:10.1002/ajh.26367 · Cited by 429
“ibrutinib in five patients and three distinct mutations in PLCgamma2 in two patients.(117) The C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib.”
BackgroundJones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30909-9 · Cited by 383
Self-citationGoyal, L., Shi, L., Liu, L. Y., de la Cruz, F. F., Lennerz, J. K., Raghavan, S., Leschiner, I., Elagina, L., Siravegna, G., Ng, R. W. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0182 · Cited by 384
“Notably, whereas resistance to other irreversible kinase inhibitors frequently arises due to mutations of cysteine residues that mediate covalent binding (34, 35), no mutations at the covalent binding site of TAS-120 (C492) were identified in any of the 4 patients studied in the current report.”
BackgroundMitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361
“Reference lists for sSNVs and sINDELs in known putative CLL driver genes as well as for recurrent CNAs were concatenated based on previous sequencing studies of large CLL cohorts (Wang et al., 2011; Quesada et al., 2012; Landau et al., 2013, 2015; Puente et al., 2015).”
InfluentialFarooqui, M. Z. H., Valdez, J., Martyr, S. E., Aue, G., Saba, N. S., Niemann, C. U., Herman, S. E. M., Tian, X., Marti, G. E., Soto, S., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71182-9 · Cited by 376
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Ercan, D., Choi, H. G., Yun, C.-H., Capelletti, M., Xie, T., Eck, M. J., Gray, N. S., & Jänne, P. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2789 · Cited by 368
“Furthermore, recent studies have also identified mutations in C481 (C481S), the analogous cysteine residue to C797 in EGFR, in patients with chronic lymphocytic leukemia treated with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib suggesting that mutations in this conserved residue may be a common mechanism of ac…”
BackgroundEGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Re, M. D., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 390
An overview of PROTACs: a promising drug discovery paradigm
Zi, L., Hu, M., Yu, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 380
“However, it has been revealed that a cysteine to serine mutation at position 481 of BTK (C481S) is what causes acquired resistance to ibrutinib [112].”
BackgroundOutcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Jain, P., Keating, M. J., Wierda, W. G., Estrov, Z. E., Ferrajoli, A., Jain, N., George, B., James, D. F., Kantarjian, H. M., Burger, J. A., et al. (2015) · Blood · doi:10.1182/blood-2014-09-603670 · Cited by 337
“Characteristics of patients who discontinued ibrutinib Characteristic Category Overall, N 5 33 Age, years Median (range) 61 (36-83) White blood cell, K/mL Median (range) 24 (2-323) Rai stage, 3-4 Advanced 76% CD38, .”
BackgroundSelf-citationBurger, J. A., Landau, D. A., Taylor-Weiner, A., Bozic, I., Zhang, H., Sarosiek, K., Wang, L., Stewart, C., Fan, J., Hoellenriegel, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11589 · Cited by 345
“Nonetheless, in this patient, the previously reported BTK-C481S mutation was detected by WES, by deep sequencing at the time of relapse and by RNA-sequencing (RNA-seq) of the same sample (Supplementary Fig.”
InfluentialChemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Furman, R. R., Cheng, S., Lu, P., Setty, M., Perez, A. R., Guo, A., Racchumi, J., Xu, G., Wu, H., Ma, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1402716 · Cited by 305
Self-citationSun, Y., Zhao, X., Ding, N., Gao, H., Wu, Y., Yang, Y., Zhao, M., Hwang, J., Song, Y., Liu, W., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0055-1 · Cited by 295
Postibrutinib outcomes in patients with mantle cell lymphoma
Martin, P., Maddocks, K. J., Leonard, J. P., Ruan, J., Goy, A. H., Wagner‐Johnston, N. D., Rule, S. A., Advani, R. H., Iberri, D. J., Phillips, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-10-673145 · Cited by 298
“The samemutation has been reported in chronic lymphocytic leukemia and MCL (1 patient from this series was included in an earlier publication).(2,11) These numbers are small but consistent with the hypothesis that BTKmutation as amechanism of ibrutinib resistance in MCL is not common and that other mechanisms are like…”
BackgroundSelf-citationThe molecular pathogenesis of chronic lymphocytic leukaemia
Fabbri, G., & Dalla‐Favera, R. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.8 · Cited by 290
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Hallek, M. J. (2017) · American Journal of Hematology · doi:10.1002/ajh.24826 · Cited by 296
“Six initial patients with acquired resistance to ibrutinib therapy were examined by whole-exome sequencing.(104) A cysteine-toserine mutation in BTK at the binding site of ibrutinib was found in 5 patients and 3 distinct mutations in PLCgamma2 were identified in 2 patients.”
The nuclear export protein XPO1 — from biology to targeted therapy
Azmi, A. S., Uddin, M. H., & Mohammad, R. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00442-4 · Cited by 291
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G. S., Brown, J., Lau, A., Pratt, G., et al. (2015) · Blood · doi:10.1182/blood-2015-05-644872 · Cited by 288
The ins and outs of selective kinase inhibitor development
Müller, S., Chaikuad, A., Gray, N. S., & Knapp, S. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1938 · Cited by 276
Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0098 · Cited by 273
“No gainof-function R665W mutation in the downstream PLCγ2 observed in ibrutinib relapse in CLL (23) was detected (Supplementary Table S5).”
BackgroundInfluentialSelf-citationMechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors
Wang, E., Mi, X., Thompson, M. C., Montoya, S., Notti, R. Q., Afaghani, J., Durham, B. H., Penson, A., Witkowski, M. T., Lu, S. X., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2114110 · Cited by 272
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñan, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 274
“The commonest cause of resistance is the C481 to serine substitution in BTK (Woyach et al., 2014, 2017; Hamasy et al., 2017; Quinquenel et al., 2019).”
BackgroundChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
Hallek, M. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.23979 · Cited by 275
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Wen, T., Wang, J., Shi, Y., Qian, H., & Liu, P. (2020) · Leukemia · doi:10.1038/s41375-020-01072-6 · Cited by 276
“SH2 (BTK Thr316) domains of BTK have been discovered [110].”
BackgroundPROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Kortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698092 · Cited by 255
“The acquisition or the selection of mutants under the selective pressure of targeted therapy has been shown be a key driver of the development of drug resistance in other hematologic malignancies (eg, BCR-ABL mutations in imatinib-treated chronic myeloid leucemia(22) or BTK mutations in chronic lymphocytic leukemia pa…”
BackgroundPhase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma
Grommes, C., Tang, S. S. K., Wolfe, J., Kaley, T. J., Daras, M., Pentsova, E. I., Piotrowski, A. F., Stone, J. B., Lin, A. L., Nolan, C. P., et al. (2018) · Blood · doi:10.1182/blood-2018-09-875732 · Cited by 249
Thompson, P. A., O'Brien, S. M., Wierda, W. G., Ferrajoli, A., Stingo, F. C., Smith, S. C., Burger, J. A., Estrov, Z. E., Jain, N., Kantarjian, H. M., et al. (2015) · Cancer · doi:10.1002/cncr.29566 · Cited by 251
“Patients with del(17p) and/or a complex metaphase karyotype (CKT) may be more likely to develop these mutations.(6) The optimal treatment for patients”
BackgroundChronic lymphocytic leukaemia: from genetics to treatment
Bosch, F., & Dalla‐Favera, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0239-8 · Cited by 259
Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor
Yu, H. A., Tian, S. K., Drilon, A. E. D. C., Borsu, L. A., Riely, G. J., Arcila, M. E., & Ladanyi, M. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1066 · Cited by 245
Diagnosis and Treatment of Chronic Lymphocytic Leukemia
Shadman, M. S. (2023) · JAMA · doi:10.1001/jama.2023.1946 · Cited by 261
Treatment of Chronic Lymphocytic Leukemia
Burger, J. A. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1908213 · Cited by 243
ten Hacken, E., & Burger, J. A. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.07.009 · Cited by 234
“PLC2) have been linked to resistance [179].”
InfluentialThe influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 234
B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma
Young, R. M., Shaffer, A. L., Phelan, J. D., & Staudt, L. M. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.01.008 · Cited by 230
“Moreover, CLL patients not only disproportionately use the same VH gene segment, but unrelated patients can have nearly identical V region sequences, constructed from the same VH DH and JH segments and paired with the same light chain variable regions as well.”
BackgroundInfluentialCervantes-Gomez, F., Lamothe, B., Woyach, J. A., Wierda, W. G., Keating, M. J., Balakrishnan, K., & Gandhi, V. V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2809 · Cited by 224
Self-citationGuo, W., Qi, X., Yu, X., Liu, Y., Chung, C.-I., Bai, F., Lin, X., Lu, D., Wang, L., Chen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17997-6 · Cited by 228
Self-citationSecond-generation inhibitors of Bruton tyrosine kinase
Wu, J., Liu, C., Tsui, S. T., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0313-y · Cited by 218
“In addition, resistance to ibrutinib has been observed [54, 55].”
BackgroundThe recurrent architecture of tumour initiation, progression and drug sensitivity
Califano, A., & Alvarez, M. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.124 · Cited by 203
Agarwal, R., Chan, Y.-C., Tam, C. S. L., Hunter, T., Vassiliadis, D., Teh, C. E., Thijssen, R., Yeh, P. S.-H., Wong, S. Q., Ftouni, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0243-z · Cited by 207
Deng, J., Isik, E., Fernandes, S. M., Brown, J. R., Letai, A. G., & Davids, M. S. (2017) · Leukemia · doi:10.1038/leu.2017.32 · Cited by 202
Niemann, C. U., Herman, S. E. M., Marić, I., Gómez‐Rodríguez, J., Biancotto, A., Chang, B. Y., Martyr, S. E., Stetler‐Stevenson, M., Yuan, C. M., Calvo, K. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1965 · Cited by 206
“However, continued therapywith ibrutinib is required, and some patients, especially those with adverse disease features may eventually develop resistance to ibrutinib (28).”
BackgroundSelf-citationDreger, P., Schetelig, J., Andersen, N. S., Corradini, P., van Gelder, M., Gribben, J. G., Kimby, E. K., Michallet, M., Moreno, C., Stilgenbauer, S., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586826 · Cited by 203
“For example, mutations of BTK or BTK downstream targets such as PLCy2may preexist or emerge under ibrutinib exposure and indicate imminent resistance.(67) What is the long-term toxicity? Although the short-term toxicity of BCRi/BCL2a is in most cases mild and easily manageable, there is no information about long-term…”
BackgroundSelf-citationClonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Herling, C., Abedpour, N., Weiss, J. M., Schmitt, A., Jachimowicz, R. D., Merkel, O., Cartolano, M., Oberbeck, S., Mayer, P., Berg, V., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03170-7 · Cited by 202
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Quek, L. S., David, M. D., Kennedy, A., Metzner, M., Amatangelo, M. D., Shih, A. H., Stoilova, B., Quivoron, C., Heiblig, M., Willekens, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0115-6 · Cited by 199
van Bruggen, J. A. C., Martens, A. W. J., Fraietta, J. A., Hofland, T., Tonino, S. H., Eldering, E., Levin, M.-D., Siska, P. J., Endstra, S., Rathmell, J. C., et al. (2019) · Blood · doi:10.1182/blood.2018885863 · Cited by 187
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
Mato, A. R., Nabhan, C., Barr, P. M., Ujjani, C. S., Hill, B. T., Lamanna, N., Skarbnik, A. P. Z., Howlett, C., Pu, J. J., Sehgal, A. R., et al. (2016) · Blood · doi:10.1182/blood-2016-05-716977 · Cited by 195
“Baseline patient characteristics and KI dosing Characteristic Result (range) Ibrutinib as first KI Idelalisib as first KI Total (n)Combined dataset Median age at diagnosis 60 y (33-89) 60 (33-89) 62 (43-79) 178 Median number prior therapies 3.0 (0-11) 3 (0-11) 2 (0-8) 178 Elevated LDH at first KI 63% 67% 50% 125 B sym…”
BackgroundInfluentialBruton Tyrosine Kinase Inhibitors
Burger, J. A. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000412 · Cited by 200
Choi, M. Y., Widhopf, G. F., Ghia, E. M., Kidwell, R. L., Hasan, M. K., Yu, J., Rassenti, L. Z., Chen, L., Chen, Y., Pittman, E. I., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.05.018 · Cited by 197
“Toxicity limits the long-term tolerability of some of these agents, and resistance due to acquired mutations is a concern (Woyach et al., 2014).”
Chen, S.-S., Chang, B. Y., Chang, S., Tong, T., Ham, S. D., Sherry, B. A., Burger, J. A., Rai, K. R., & Chiorazzi, N. (2015) · Leukemia · doi:10.1038/leu.2015.316 · Cited by 193
Self-citationRuella, M., Kenderian, S. S., Shestova, O. E., Fraietta, J. A., Qayyum, S., Zhang, Q., Maus, M. V., Liu, X., Nuñez-Cruz, S., Klichinsky, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1527 · Cited by 190
“The mechanisms of resistance are currently poorly understood but are thought to involvemutations in BTK that impair ibrutinib binding, or activating mutations of the enzyme PLCg2 resulting in constitutive BTK-independent cell signaling (10,11).”
BackgroundHeterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Smith, C. C., Paguirigan, A. L., Jeschke, G. R., Lin, K. C., Massi, E., Tarver, T. C., Chin, C.-S., Asthana, S., Olshen, A. B., Travers, K. J., et al. (2017) · Blood · doi:10.1182/blood-2016-04-711820 · Cited by 185
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma
Krysiak, K., Gomez, F., White, B. S., Matlock, M. K., Miller, C. A., Trani, L., Fronick, C. C., Fulton, R. S., Kreisel, F. H. C., Cashen, A. F., et al. (2016) · Blood · doi:10.1182/blood-2016-07-729954 · Cited by 197
Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia
Leblond, V., Kastritis, E., Advani, R. H., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711234 · Cited by 181
“In CLL, resistance to ibrutinib with BTK C481S mutation or PLCg2 mutations have been described in few patients and remain under investigation.(54) Novel BTK inhibitors are in clinical development and may offer additional choices: CC-292, ONO-4059, ACP-196, and BGB-3111.”
BackgroundCheah, C. Y., Chihara, D., Romaguera, J. E., Fowler, N. H., Seymour, J. F., Hagemeister, F. B., Champlin, R. E., & Wang, M. L. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv111 · Cited by 179
“In CLL patients with ibrutinib resistance, point substitutions in BTK (C481S) and PLCG2 (R665W) have been described [11].”
BackgroundThe evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
Landau, D. A., Sun, C., Rosebrock, D., Herman, S. E. M., Fein, J., Sivina, M., Underbayev, C., Liu, D., Hoellenriegel, J., Ravichandran, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02329-y · Cited by 176
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Montoya, S., Bourcier, J., Noviski, M., Lu, H., Thompson, M. C., Chirino, A., Jahn, J., Sondhi, A. K., Gajewski, S., Tan, Y. S. (., et al. (2024) · Science · doi:10.1126/science.adi5798 · Cited by 175
“Specifically, acquired mutations atthe C481 residue of BTK conferresistancetoallcovalentBTKinhibitors ( 11 – 14 ).”
BackgroundPROTACs to address the challenges facing small molecule inhibitors
Martín-Acosta, P., & Xiao, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112993 · Cited by 192
Camicia, R., Winkler, H. C., & Hassa, P. O. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0474-2 · Cited by 177
“Moreover, an ongoing early dose escalation and dose expansion phase I study is evaluating the safety and efficacy of idelalisib in combination with the novel BTK inhibitor ONO-4059 in patients with relapsed/refractory ABC-DLBCL (Additional file 1: Table S14).”
BackgroundInfluentialLiu, T.-M., Woyach, J. A., Zhong, Y., Lozanski, A., Lozanski, G., Dong, S., Strattan, E., Lehman, A., Zhang, X., Jones, J. A., et al. (2015) · Blood · doi:10.1182/blood-2015-02-626846 · Cited by 178
“We have previously reported that relapse during ibrutinib therapy is associated with the acquisition of specific gene mutations.(13,22) Besides C481S at BTK that directly impairs the targeting effect of ibrutinib, our previous studies identified somatically acquired PLCG2 variants and illustrated how those mutations a…”
BackgroundSelf-citationThe BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Reiff, S. D., Mantel, R., Smith, L. L., Greene, J. T., Muhowski, E. M., Fabian, C. A., Goettl, V. M., Tran, M., Harrington, B. K., Rogers, K. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1409 · Cited by 165
“Consistent with the previous report (23), the BTK C481S mutation severely abrogated the off-rate kinetics of ibrutinib, dramatically affecting the binding affinity and the residence time.”
BackgroundSelf-citationCampo, E., Cymbalista, F., Ghia, P., Jaeger, U., Pospíšilová, Š., Rosenquist, R., Schuh, A., & Stilgenbauer, S. (2018) · Haematologica · doi:10.3324/haematol.2018.187583 · Cited by 166
Self-citationSingle-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Bartlett, N. L., Costello, B. A., LaPlant, B. R., Ansell, S. M., Kuruvilla, J. G., Reeder, C. B., Thye, L. S., Anderson, D. M., Krysiak, K., Ramirez, C. A., et al. (2017) · Blood · doi:10.1182/blood-2017-09-804641 · Cited by 161
Alu, A., Lei, H., Han, X., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01353-w · Cited by 159
“Mutations at the BTKCys481 residues significantly compromise the efficacy and caused resistance to the irreversible BTKi [102].”
BackgroundSecondary mutations as mediators of resistance to targeted therapy in leukemia
Daver, N. G., Cortes, J. E., Ravandi, F., Patel, K. P., Burger, J. A., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-10-605808 · Cited by 164
“95 IPI-145 is currently being evaluated for therapy of CLL. Alternatively, treatment with the BCL-2 antagonist ABT-199 will be explored, and in the absence of clinical trial options, some patients have been treated with combinations of anti-CD20 mAbs and high-dose corticosteroids.”
BackgroundCheng, S., Guo, A., Lu, P., Ma, J., Coleman, M., & Wang, Y. L. (2014) · Leukemia · doi:10.1038/leu.2014.263 · Cited by 162
Herman, S. E. M., Montraveta, A., Niemann, C. U., Mora-Jensen, H. I., Gulrajani, M., Krantz, F., Mantel, R., Smith, L. L., McClanahan, F., Harrington, B. K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0463 · Cited by 156
“Resistance developsmost commonly throughmutations in BTKor PLCg2, suggesting that BTK is indeed a critically important target for ibrutinib (16, 17).”
BackgroundSelf-citationChen, L., Fu, W., Zheng, L., Liu, Z., & Liang, G. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01310 · Cited by 169
Berchuck, J. E., Facchinetti, F., Ditoro, D. F., Baiev, I., Majeed, U., Reyes, S., Chen, C. T., Zhang, K., Sharman, R., Usón, P. L. S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.150 · Cited by 152
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia
Guièze, R., & Wu, C. J. (2015) · Blood · doi:10.1182/blood-2015-02-585042 · Cited by 151
“10 Remarkably, various individuals subjects across studies have been detected to harbor multiple subclones with mutation in PLCγ2, consistent with convergent evolution occurring within these patients.(57,59,66,67) These findings support the idea of individualized evolutionary trajectories taken on by different CLL sub…”
BackgroundUnification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
Zhao, X., Lwin, T., Silva, A., Shah, B. D., Tao, J., Fang, B., Zhang, L., Fu, K., Li, J., Li, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14920 · Cited by 154
The role of reversible and irreversible covalent chemistry in targeted protein degradation
Kiely‐Collins, H., Winter, G. E., & Bernardes, G. J. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.005 · Cited by 160
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
Haselmayer, P., Camps, M., Liu‐Bujalski, L., Nguyen, N. T. K., Morandi, F., Head, J. C., O’Mahony, A., Zimmerli, S. C., Bruns, L., Bender, A. T., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800583 · Cited by 143
“These reports showed a loss of potency of ibrutinib when Cys(481) was mutated to serine (48).”
BackgroundInfluentialC hronic lymphocytic leukemia (CLL)— T hen and now
Rai, K. R., & Jain, P. (2015) · American Journal of Hematology · doi:10.1002/ajh.24282 · Cited by 154
“other TKI’s, mechanisms of ibrutinib [121] and BTK resistance [122],”
BackgroundYamaura, T., Nakatani, T., Uda, K., et al. (2017) · Blood · doi:10.1182/blood-2017-05-786657 · Cited by 145
Ringheim, G. E., Wampole, M. E., & Oberoi, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662223 · Cited by 151
The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy
Crofford, L. J., Nyhoff, L. E., Sheehan, J. H., & Kendall, P. L. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1152888 · Cited by 142
“Antigen-BCR binding triggers a signaling pathway in which BTK is recruited to the cell membrane from the cytosol, docks with the linker protein BLNK and phosphorylates PLCγ2, with downstream calcium flux and cellular activation via nuclear translocation of transcription factors NFκB and NFAT.”
InfluentialPathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatment
Young, R. M., Phelan, J. D., Wilson, W. H., & Staudt, L. M. (2019) · Immunological Reviews · doi:10.1111/imr.12792 · Cited by 155
Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S., Bociek, G., Brander, D. M., Brown, J. R., Chanan-Khan, A. A., Chávez, J. C., Coutre, S. E., et al. (2020) · PubMed · doi:10.6004/jnccn.2020.0006 · Cited by 142
Self-citation
Metadata
- Authors
- Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., Dave, S. S., Zhang, J., Yilmaz, A. S., Jaglowski, S. M., Blum, K. A., Lozanski, A., Lozanski, G., James, D. F., Barrientos, J. C., Lichter, P., Stilgenbauer, S., Buggy, J. J., Chang, B. Y., Johnson, A. J., & Byrd, J. C.
- Affiliations
- German Cancer Research Center (DE)
- Weill Cornell Medicine (US)
- Pharmacyclics (United States) (US)
- Janssen (Belgium) (BE)
- Duke University (US)
- The Ohio State University (US)
- Northwell Health (US)
- Universität Ulm (DE)
- ORCID
- Woyach, Jennifer A.
- Furman, Richard R.
- Zapatka, Marc
- Ruppert, Amy S.
- Li, Daniel Hsieh-Hsin
- Versele, Matthias
- Zhang, Jenny
- Yilmaz, Ayse Selen
- Jaglowski, Samantha M.
- Blum, Kristie A.
- Lozanski, Gerard
- James, Danelle F.
- Barrientos, Jacqueline C.
- Lichter, Peter
- Stilgenbauer, Stephan
- Chang, Betty Y.
- Johnson, Amy J.
- Byrd, John C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-06-12
- Volume
- 370
- Issue
- 24
- Pages
- 2286-2294
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4144824
- OpenAlex
- W2067064694
- Cited by
- 1,275
- References
- 34
- Citations by year
- 2026: 50 · 2025: 77 · 2024: 91 · 2023: 99 · 2022: 102 · 2021: 143 · 2020: 122 · 2019: 99 · 2018: 98 · 2017: 126 · 2016: 118 · 2015: 108 · 2014: 39
- FWCI
- 58.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16, 5k12ca133250-17, 2p30ca014236-51)
- National Cancer Institute (P30‐CA014236, R01CA183444, P01CA095426, K12‐CA133250, P50CA140158, K23 CA178183, R01CA177292, P30CA016058, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- ibrutinib, Bruton's tyrosine kinase, chronic lymphocytic leukemia, drug resistance, B cell receptor signaling, irreversible kinase inhibitors, relapsed disease
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Aged, Binding Sites, Humans, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Receptors, Antigen, B-Cell, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Point Mutation, Sequence Analysis, DNA, Drug Resistance, Neoplasm, Phospholipase C gamma, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
